Navigation Links
Sosei Announces Outcome of Strategy Review
Date:5/13/2008

TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the outcome of its strategy review.

In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has necessitated a halt to the Phase III trials Sosei has taken decisive action to cut costs, streamline its operation and to secure the future of the business until it becomes a significant income generating business from NVA237/QVA149 in a few years time.

- Sosei is closing its Chesterford operation and Sosei R&D's

continuing business will relocate to London in due course. This will

reduce UK headcount by c 40 staff and provide a full years cost saving of

around $4M.

- Sosei will no longer operate a drug discovery unit.

- Sosei R&D will maintain the rights to NVA237/QVA149 but seek

to out-license or sell all other assets generated in the UK including

AD923 and its discovery assets whilst seeking to retain some rights for

the Asian market.

- Tokyo will continue to develop Norlevo and explore other

in-licensing opportunities.

This restructuring and portfolio review will provide Sosei with at least two years cash based on the post-restructuring cash burn including a budget allocation to explore some late stage product opportunities for future expansion but without the inclusion of any income from licensing or sales deals for its compounds.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical mark
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
2. BD Announces Acquisition of Cytopeia
3. Chindex International Announces Shelf Registration, Related Strategy and Guidance
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
6. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
11. Aton Pharma Announces Distribution Partnership in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... December 16, 2014 “Never say, ... Philipps- Universität Marburg’s Department of Physics, advises young ... the newly released SPIE Women in Optics ... too shy to ask questions.” , In the ... and mathematics) occupations ranging from university professor and ...
(Date:12/17/2014)... Long Beach, CA (PRWEB) December 17, 2014 ... Technology, Inc. to provide a larger packaged waste water ... district in King Abdullah Economic City (KAEC). Two years ... for EMAAR’s Jeddah Gate Development, serving two residential towers ... plant capacity is over a quarter million gallons per ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... System (RTLS) Market, ORLANDO, Fla., Feb. 25 ... in precision ultra wideband (UWB),real- time location systems ... (PLUS) product line at the HIMSS08,healthcare conference and ... patented UWB technology, enables RTLS solutions to move ...
... Strativa,Pharmaceuticals, the proprietary products division of a wholly ... PRX ) today,announced that its development partner, Immtech ... discontinue the development program for,pafuramidine maleate, an investigative ... that it had received additional,reports of adverse events ...
... at the upcoming World ... Congress of Anesthesiologists Meeting, IRVINE, Calif., ... Measure-Through Motion and Low Perfusion pulse,oximetry, announced that it ... hemoglobin (SpHb(TM)) and oxygen content,(SpOC(TM)) monitoring at the World ...
Cached Biology Technology:Time Domain Showcases Precision Location Capability of Ultra Wideband PLUS Product Line at HIMSS 2008 2Time Domain Showcases Precision Location Capability of Ultra Wideband PLUS Product Line at HIMSS 2008 3Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 3Masimo Announces Continuous Noninvasive Total Hemoglobin 2Masimo Announces Continuous Noninvasive Total Hemoglobin 3Masimo Announces Continuous Noninvasive Total Hemoglobin 4
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Access to Research Careers) Program has announced the travel ... Advanced Course in Immunology at The University of Minnesota ... These awards are meant to promote the entry ... mainstream of the basic science community and to encourage ...
... A deep-sea mystery has been solved with the discovery that ... cod and mackerel, use the same buoyancy control as whales. ... Oceanography , researchers from British Antarctic Survey describe how Southern ... ,hibernates, in the deep ocean during winter when seas are ...
... out of a comic book or a science fiction movie ... two investigators at the Wellman Center for Photomedicine at Massachusetts ... appear in the journal Nature Photonics and is ... Seok Hyun Yun, PhD, describe how a single cell genetically ...
Cached Biology News:Single GFP-expressing cell is basis of living laser device 2Single GFP-expressing cell is basis of living laser device 3